The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from PR Newswire

Questcor Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2011

Friday, January 07, 2011

Questcor Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 201118:20 EST Friday, January 07, 2011ANAHEIM, Calif., Jan. 7, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) announced today that its presentation at the 29th Annual J.P. Morgan Healthcare Conference has been rescheduled for 9:00 a.m. PT on Monday, January 10, 2011 at the Westin St. Francis Hotel in San Francisco. Questcor was originally scheduled to present at 2:00 p.m. PT on Thursday, January 13, 2011. Don M. Bailey, President and Chief Executive Officer, will review the Company's business strategy and recent corporate developments.A live audio and slides webcast of Questcor's presentation may be accessed through the Company's website at www.questcor.com. An archived replay of the presentation will be available for 90 days after the live presentation, and can also be accessed at www.questcor.com. About Questcor Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose products help patients with serious, difficult-to-treat medical conditions. Questcor markets H.P. Acthar® Gel (repository corticotropin injection), which is indicated for the treatment of acute exacerbations of multiple sclerosis in adults, and as monotherapy for the treatment of IS in infants and children under 2 years of age. It is also indicated to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus, and for the treatment of several other diseases and disorders.  Questcor also markets Doral® (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com. SOURCE Questcor Pharmaceuticals, Inc.For further information: Don Bailey of Questcor Pharmaceuticals, Inc., +1-510-400-0776, dbailey@Questcor.com; or media, Janine McCargo, +1-646-688-0425, or investors, Gregory Gin or Doug Sherk, +1-415-896-6820, all of EVC Group, for Questcor Pharmaceuticals, Inc.